Drug intelligence / Profile preview

SGA308

Development stage: Preclinical
Lead developer: BMG Pharma
Administration: Intradermal, Subcutaneous

Overview

SGA308 is an injectable aesthetic booster currently in preclinical development by BMG Pharma. It is specifically designed for the treatment of photoaging, a condition characterized by premature skin aging and damage resulting from chronic exposure to ultraviolet (UV) radiation. As part of BMG Pharma's aesthetic medicine portfolio, SGA308 is intended to rejuvenate skin quality and address structural degradation. While the specific molecular composition has not been fully disclosed, BMG Pharma typically focuses on advanced polymer technologies and hyaluronic acid-based complexes to restore the extracellular matrix and improve skin hydration and elasticity.

Other names: SGA308 Photoaging BoosterSGA-308 Photoaging BoosterSGA 308 Photoaging Booster

Beyond the preview

Go deeper on SGA308.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SGA308.

Explore the full profile